论文部分内容阅读
目的观察甲羟孕酮应用于肺癌化疗的不良反应,并评价患者的生活质量。方法选取2012年1月至2013年6月间收治的68例肺癌患者,分为试验组和对照组,每组34例。试验组患者在联合化疗基础上给予甲羟孕酮治疗,对照组患者只给予联合化疗治疗,比较两组患者的不良反应和生活质量。结果两组患者的不良反应和生活质量比较,差异均有统计学意义(P<0.05)。结论甲羟孕酮能有效降低肺癌患者化疗后出现的腹泻、肝肾功能损害等不良反应,显著提高患者的进食量,增加患者的体重,值得临床进一步推广。
Objective To observe the adverse reactions of medroxyprogesterone in lung cancer chemotherapy and to evaluate the quality of life of patients. Methods Sixty-six patients with lung cancer who were admitted from January 2012 to June 2013 were divided into experimental group and control group, 34 cases in each group. Patients in the test group were treated with medroxyprogesterone acetate on the basis of combination chemotherapy, while patients in the control group were given chemotherapy alone. Adverse reactions and quality of life were compared between the two groups. Results There were significant differences in adverse reactions and quality of life between the two groups (P <0.05). Conclusion Medroxyprogesterone can effectively reduce adverse reactions such as diarrhea, liver and kidney dysfunction after chemotherapy in patients with lung cancer, significantly improve the patient’s food intake and increase the patient’s weight, which is worth further clinical promotion.